Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_1100_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
02.09.2026
Размер:
21 Мб
Скачать
Preventing Pancreatic Fistula Following Distal Pancreatectomy
Bharath D. Nath and Mark P. Callery
30
Overview
Postoperative pancreatic fistula (POPF) is a feared complication following distal pancreatec­tomy that contributes significantly to patient mor­bidity and mortality. While the majority of POPF can be managed conservatively, the presence of pancreatic fistula is a risk factor for the devel­opment of intra-abdominal sepsis and post-pan­createctomy hemorrhage, which individually can be life threatening. Estimates of the incidence of pancreatic fistula following distal pancreatecto­my range widely. Some centers report rates under 10 %, while others report POPF in close to 50 % of patients undergoing distal pancreatectomy. To some extent, this variation may be secondary to the method used to diagnose POPF. Uncontrolled pancreatic fistula, while less common, is the most dangerous and can evolve into other complica­tions, such as pancreatic pseudocyst and abscess. The incidence of pseudocyst as a complication of distal pancreatectomy is between 1 and 2 %. In one series of patients who underwent distal pan­createctomy for trauma, 2 of 72, or about 2.7 %, developed pancreatic pseudocyst postoperatively [1].
Numerous investigations, analyses, and clini-
cal trials devoted to identifying risk factors for
M. P. Callery () · B. D. Nath Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA e-mail: mcallery@bidmc.harvard.edu
B. D. Nath e-mail: bnath@bidmc.harvard.edu
POPF have been reported and have guided strate­gies for its management and prevention. A short list of risk factors for the development of POPF includes pancreatic texture, pathology, duct size, age, intraoperative blood loss, and others [2]. A number of technical factors have also been inves­tigated. Few of these, however, have been dem­onstrated to have an effect on the overall inci­dence of POPF, understandably to the frustration of surgeons and their patients [3]. This chapter considers proposed interventions for the reduc­tion of POPF that have been evaluated in the preoperative, intraoperative, and postoperative settings.
Diagnosis
The consensus classification scheme devised by the International Study Group on Pancreatic Fis­tula (ISGPF) in 2005 divides pancreatic fistula into three grades. In general terms, POPF is de­fined as leakage of pancreatic secretions from the pancreatic parenchyma or a disrupted pancreatic duct stump or anastomosis. The leak may result in the formation of a pseudocyst, may be drained externally via a surgical drain, or may communi­cate with another epithelialized surface [4]. How­ever, it is important to note that if there is high drain output, even a high-output pancreatic fis­tula may have no obvious abnormality on cross­sectional imaging. Clinically, the diagnosis of POPF may be heralded by a variety of symptoms and consequently should be considered in nearly all cases wherein a patient’s clinical course devi­ates from what is expected. Drain character may
T. M. Pawlik et al. (eds.), Gastrointestinal Surgery, DOI 10.1007/978-1-4939-2223-9_30, © Springer Science+Business Media New York 2015
317
318 B. D. Nath and M. P. Callery
become cloudy and grayish, which is character­istic of POPF. Amylase levels collected from the drain or collection on or after postoperative day #3 must be three times the upper limit of normal to define a leak according to the ISGPF classi­fication. Patients with pancreatic fistula have a spectrum of presentation, from patients that ap­pear well and are unlikely to have significant sequelae from the POPF (grade A), to patients that appear ill, with signs of sepsis and risk of death, and a high likelihood of reintervention and persistent drainage (grade C). Grade B falls be­tween these extremes and, in general, are patients with signs of infection, with persistent drainage, who typically require admission and inpatient management, but who typically do not require interventional procedures and who do not appear septic [4]. Since its publication, the ISGPF clas­sification scheme has been validated as a useful clinical tool, as well as a predictor of increased hospital costs, particularly in a cohort of patients undergoing pancreaticoduodenectomy [5].
Even this scheme, however, is not without limitations. Perhaps most importantly, one large series identified a latent presentation of pancre­atic fistula occurring in 3.2 % of patients under­going distal pancreatectomy. In these patients, initial drain output was notable for normal or minimally elevated amylase levels that did not meet biochemical criteria for pancreatic fistula by ISGPF definitions. Subsequently, all these patients had the diagnosis of pancreatic fistula confirmed by clinical or radiographic investiga­tion. Patients with latent fistula were more likely to have superimposed infection versus clinically evident fistula [6].
Although drain amylase measurement has been the standard since the ISGPF consensus statement, recent investigations have suggested that drain lipase may be equally effective at de­tecting fistulas and possibly superior in terms of sensitivity and specificity in detecting clinically relevant fistulas [7].
Another limitation arises from the broad clas­sification of pancreatic fistula from all operations within the ISGPF system. Recent work has sug­gested that there was little difference in clinical impact between grade B and C pancreatic fistula
among patients undergoing distal pancreatecto­my, as well as only marginally increased hospital costs, versus robust increases in hospital costs between patients who had grade B and C fistula following pancreaticoduodenectomy [8].
Prevention
Identifying Risk Factors
For pancreaticoduodenectomy, a fistula risk score has been recently developed that has been shown to be highly predictive of POPF. This score assigns points based on gland texture, gland pathology, duct diameter, and intraopera­tive blood loss. In general, high blood loss, soft gland texture, and smaller duct diameter confer increased risk of POPF, whereas pancreatic ad­enocarcinoma and pancreatitis as the indication for pancreaticoduodenectomy confer protection for the development of pancreatic fistula ver­sus other diagnoses. Also of note, higher fistula risk scores correlated with greater incidence of clinically relevant (ISGPF grade B or C) fistula [9]. The adaptation of this risk score to patients undergoing distal pancreatectomy is yet to be validated; however, at least one published study indicates that this scoring system may have limi­tations in the setting of distal pancreatectomy. In that study, risk factors for pancreatic fistula after stapled gland transection in patients undergoing distal pancreatectomy were examined, and in a multivariate analysis, only the presence of diabe­tes and the use of a 4.1-mm staple cartridge were associated with increased risk of pancreatic fis­tula formation [10].
Some retrospective data have supported the conclusions drawn with regard to risk for pancre­atic fistula after pancreaticoduodenectomy in the setting of distal pancreatectomy. A retrospective case-matched analysis looked at histopathologic features of patients with fistula and matched pa­tient controls and found that gland fat content, smaller main duct size, and the lack of stigmata of chronic pancreatitis or interlobular fibrosis were correlated with increased risk of POPF. This study included 9 patients who underwent
31930 Preventing Pancreatic Fistula Following Distal Pancreatectomy
pancreaticoduodenectomy as well as 16 patients who underwent distal pancreatectomy. A score was created using these and other characteristics, which had 92 % sensitivity and 84 % specificity for the postoperative development of pancreatic fistula [11].
Role of Octreotide
The somatostatin analog octreotide has been the subject of numerous investigations in pancreatic surgery and specifically in the prevention of the formation of pancreatic fistula following pan­creaticoduodenectomy or distal pancreatectomy. The biologic plausibility of the effectiveness of octreotide is significant; by decreasing pancre­atic secretions, pressure gradients across the pan­creatic ductal anastomosis or closure would be decreased, thereby resulting in decreased fistula rates. Alternatively, where a fistula has already formed, octreotide might have the potential to convert a high-output fistula into a low-output fistula, decreasing the likelihood of complica­tions and increasing the chances of a spontane­ous closure. However, most studies to date have failed to definitively identify a role for octreotide in pancreatic surgery. Furthermore, the biologic rationale, while emotionally appealing, may not stand up to scientific scrutiny; a 2013 single­institution trial measured the effect of octreotide in patients who underwent a pancreaticoduode­nectomy by directly measuring exocrine output using intraductal pancreatic catheters and failed to demonstrate any significant difference be­tween octreotide and placebo in the volume of pancreatic exocrine secretion [12].
Recently, a multicenter randomized controlled trial was undertaken to answer the question of whether octreotide administration was of ben­efit in pancreatic surgery. Enrolling 230 patients with slightly more than half-randomized to the octreotide group, the study failed to demonstrate any overall benefit in octreotide administration. While a subgroup analysis suggested some ben­efit for patients with small duct diameters, the study overall was significantly weakened by a significant increase in the incidence of intraduct-
al fibrin sealant administration in the octreotide group [13].
Role of Pancreatic Stenting
Stenting of the main pancreatic duct at the am­pulla has been investigated as a method to pre­vent postoperative fistula formation after distal pancreatectomy. This again has a clear anatomic rationale, as decompression of the pancreatic tree via drainage across the ampulla would have the effect of decreasing pressure against the pancre­atic stump, thereby reducing the likelihood of leakage from the resection margin. Retrospective data from several centers initially demonstrated some success with the technique. One small se­ries published in 2008 noted a 20 % incidence of mild pancreatitis but no instances of pancreatic leak among ten patients who underwent distal pancreatectomy with prior endoscopic placement of transampullary stent [14]. A second retrospec­tive series involved the intraoperative placement of transampullary stents. In this series, the sur­geons identified the transected duct at the resec­tion margin of the distal pancreatectomy and subsequently advanced a pediatric feeding tube into the duodenum. The transected end of the duct was then ligated. The authors were able to demonstrate an association of intraoperative stent placement with decreased pancreatic fistula rates as well as decreased overall length of stay [15].
However, in 2012, a randomized prospective trial was performed in which patients were as­signed either to distal pancreatectomy alone or to distal pancreatectomy with prior transpapillary stent placement. That trial failed to show a bene­fit of preoperative stenting of the pancreatic duct and in fact demonstrated a trend toward a signifi­cantly increased rate of pancreatic fistula among patients with preoperative stent placement [16]. An example that highlights the significant diffi­culty in obtaining robust best practice standards in this area comes from a similar controversy in pancreaticoduodenectomy. Although the opera­tions are significantly different, prior retrospec­tive examination of patients undergoing pan­creaticoduodenectomy with intraoperative stent
320 B. D. Nath and M. P. Callery
placement demonstrated no benefit for the pre­vention of POPF [17]. However, a randomized trial performed around the same time actually demonstrated a benefit to intraoperative pancre­atic stenting [18].
Dissection and Management of the Pancreatic Stump
The management of the pancreatic stump cre­ated during a distal pancreatectomy has also been the subject of some controversy. Histori­cally, techniques of transection of the pancreatic stump included sharp division and oversewing of the transected surface. With the advent of sta­plers, controversy has arisen with regard to their use in transection of the pancreatic body. Some authors initially suggested that hand-sewn clo­sures had lower rates of fistula, whereas others demonstrated superior results with stapler use [19]. Recently, a multivariate analysis identified increased thickness of the pancreatic body as a risk factor for failure with stapled transections. Additionally, use of a double-row (as opposed to a triple-row) stapler load was associated with in­creased risk of fistula [20].
Anatomic techniques have also been widely investigated. A recently published randomized controlled trial compared stump reinforcement with fibrin glue and a falciform patch to no rein­forcement among patients undergoing distal pan­createctomy with stapled or hand-sutured stump closure techniques, and found identical rates of pancreatic fistula among the two groups [21].
Another group of techniques described in the literature include the creation of anastomoses be­tween the pancreatic stump and either the bowel or the stomach. One prospective case series de­scribed 21 patients undergoing distal pancreatec­tomy with the creation of pancreaticogastrosto­my, and the authors were able to report a 0 % rate of grade B or C pancreatic fistula [22]. Another group in a retrospective review demonstrated a statistically significant elimination in the num­ber of pancreatic fistula when a roux-en-Y limb was brought up to provide distal drainage to the transected pancreatic stump after distal pancre-
atectomy [23]. Indeed, numerous studies have re­ported somewhat favorable results with creation of an anastomosis at the distal pancreatic stump [24]. A large series by Kleef et al. [25] examined 302 patients undergoing distal pancreatectomy with an overall fistula rate of 12 %. Data were gathered prospectively, and four main techniques of pancreatic stump management were described: (1) pancreaticojejunostomy; (2) seromuscular patch; (3) suture of the duct with polydioxanone (PDS) stitch followed by parenchymal closure with PDS suture, with or without collagen patch; (4) closure with a stapler, primarily with a vas­cular load. In this series, a stapled anastomosis was associated with a higher rate of fistula for­mation. As this was a retrospective, single-center review, certain subgroup analyses such as a strict comparison of patient characteristics between the various closure techniques were not reported [25]. Additionally, the use of nonvascular stapler loads, which the authors suggest were occasion­ally used, may be quite significant. One single­center study suggested that the rate of pancreatic fistula was much lower when a vascular (2.5 mm) cartridge was utilized instead of a standard car­tridge or a hand-sewn technique [26]. More re­cently, a large multicenter trial was conducted to answer the question of whether a stapled or hand­sewn technique prevented POPF. The DISPACT trial randomized patients into a stapled or hand­sewn closure of the pancreatic stump. The prima­ry endpoints included combined mortality and/or the detection of pancreatic fistula prior to post­operative day #7. Secondary endpoints included detection of pancreatic fistula up until postopera­tive day #30. No difference in fistula rates was described between the two groups. Additionally, outcomes among a range of clinical factors were similar. A post hoc analysis was conducted within the trial to determine the factors associated with the development of pancreatic fistula and did not reveal any factor to be causative in a multivariate analysis [27].
Ligation of the main pancreatic duct, where technically feasible, has been reported to dra­matically reduce the incidence of pancreatic duct leak in some studies, with conflicting reports in others. The main limitation of data addressing
32130 Preventing Pancreatic Fistula Following Distal Pancreatectomy
this technical point is that it is limited to single­institution retrospective studies. Some authors have been able to demonstrate a reduction in the rate of pancreatic fistula from greater than 30 % to less than 10 % and that the performance of duct ligation was a significant negative predictor of pancreatic fistula by multivariate analysis [28]. Notably, in that study, which included an overall pancreatic leak rate of approximately 20 %, other factors including pancreatic pathology, hand­sewn or stapled closure, octreotide use, blood transfusion, and operating time, among other factors, were all demonstrated to be unrelated to the postoperative development of pancreatic leak in a multivariate analysis. A recent retrospective review of 704 patients undergoing distal pancre­atectomy at a single institution was not able to detect a significant effect of duct ligation on the prevention of pancreatic leak, and in fact detect­ed a trend toward increased clinically significant leak rate when duct ligation was performed. Of note, however, duct ligation was employed se­lectively at this institution, and thus may have been reserved for those cases with large duct diameters or other intraoperative findings that raised concern for increased likelihood of duct leak [3].
There has been new interest in managing the transected pancreatic stump by reinforcing the stump with a mesh closure. Early retrospective data from single centers suggested that use of an absorbable mesh to reinforce the staple line of the transected pancreas reduced the rate of stump leak [29]. This method has been investi­gated with a randomized, single-blinded clinical trial with a total enrollment of 100 patients. Rein­forcement of the distal pancreatectomy resection margin with mesh reduced the rate of clinically significant (ISGPF B and C) pancreatic fistula from 20 disadvantage as the placement of a mesh significantly increas­es the cost of operation. However, a recent cost analysis suggested that patients who received mesh placement during distal pancreatectomy had overall lower hospital charges and decreased length of stay versus patients who underwent dis­tal pancreatectomy without mesh placement [31].
% to less than 2 % [30]. One potential
of this technique relates to expense,
Minimally Invasive Versus Open Techniques
Despite advances in laparoscopic and robotic approaches, the vast majority of distal pancre­atectomies continue to be performed via an open approach. Recent retrospective data have demon­strated that minimally invasive distal pancreatec­tomy is associated with decreased blood loss and shorter hospital stays than open pancreatectomy [32]. A large recent study utilizing the Nation­wide Inpatient Sample database suggested, first, that the minimally invasive approach is becom­ing more widely utilized, increasing from 2.4 to
7.3 % over a study period from 1998 to 2009. Second, that study reported that the minimally invasive approach was associated with decreased length of stay as well as decreased incidence of infectious complications, bleeding complica­tions, and blood transfusions [33]. This popula­tion-based study echoes conclusions drawn by a large multi-institutional study performed several years previously. Drawing on a combined pa­tient sample of 667 patients, with 24 % initially attempted laparoscopically, the authors were able to demonstrate lower overall complication rate, decreased blood loss, and shorter hospital stays among patients undergoing laparoscopic approach via a multivariate analysis. Notably, there was no significant difference in the pancre­atic leak rate between the open and laparoscopic approaches, although there was a nonsignificant trend favoring the laparoscopic approach [34].
More recently, the robotic approach has gen­erated significant interest as a technique for per­forming distal pancreatectomy. Retrospective analysis has suggested that the robotic approach is well suited for pancreatectomy. Fistula rates, however, remain a concern. A retrospective re­view of patients undergoing robotic pancreatic operations included 83 patients who underwent distal pancreatectomy. About 27 % were identi­fied as having a ISPGF type A pancreatic leak; 12 and 4.8 % were identified as having a grade B or C leak, respectively [35]. At our own insti­tution, we have increasingly come to utilize the robotic approach as the operation of choice for elective distal pancreatectomy. Early data based
322 B. D. Nath and M. P. Callery
on retrospective analyses have demonstrated no difference between the robotic approach and the laparoscopic approach with regard to the devel­opment of pancreatic fistula. The robotic ap­proach, however, was associated with lower rates of conversion to open in comparison with the laparoscopic approach as well as shorter opera­tive times. Additionally, oncologic outcome in­cluding nodal harvest and R0 resection were im­proved with the robotic approach. No significant difference in outcome with regard to pancreatic fistula has been demonstrated between the robot­ic and the laparoscopic approach [36].
Drain Placement and Management
Drain placement after pancreatectomy has been a subject of controversy for several years. At least one randomized trial demonstrated no benefit to drain placement after pancreatic resection; that trial, however, included both pancreaticoduode­nectomy and distal pancreatectomy [37]. More recently, retrospective data in patients undergo­ing distal pancreatectomy demonstrated that 50 % of patients who developed pancreatic fistula were given that diagnosis after the drain had been re­moved. Put another way, that data suggested that the presence of a drain was only useful for the detection of pancreatic fistula in 50 % of patients [38]. Other retrospective analyses have failed to demonstrate a benefit to peritoneal drainage after distal pancreatectomy [39]. However, our specif­ic practice has remained to leave a drain in place anterior to the stapled transection margin. In our experience, placement of a drain has the potential to control intra-abdominal fluid collections that form as a result of pancreatic stump leak, and we choose to drain nearly all cases of distal pancre­atectomy. Our approach to management of op­erative intraperitoneal drains is to monitor daily output and remove drains when drain output is less than 50cc per day, the character of the efflu­ent is serous, and the patient appears clinically well and is tolerating enteral feeding [6]. Though admittedly a practice preference, we have seen very few complications related to the actual drain itself.
Management of Complications of Pancreatic Leak
Mostly, any deviation from the expected clini­cal course in a patient who has undergone distal pancreatectomy should prompt consideration of a pancreatic leak. Pancreatic leaks may present in a latent fashion, or be clinically evident early after resection. If a drain has been left in place, ret­rospective data suggest that features of the drain prior to its removal should not be reassuring with regard to the subsequent consideration of pan­creatic fistula when a patient presents postopera­tively with fever and abdominal pain. The pre­ceding data in this chapter underscore the wide variety of strategies that have been employed to prevent pancreatic exocrine complications after distal pancreatectomy and the very limited suc­cess that any single strategy has enjoyed. Indeed, a recent survey of hepatopancreatobiliary sur­geons worldwide demonstrated that there is little consensus on the management of patients with POPF [40].
One area where there is significant consensus is the use of enteral nutrition. A recent single-in­stitution randomized controlled trial demonstrat­ed that the use of enteral, rather than parenteral, nutrition in patients with POPF was associated with a significantly higher rate of fistula closure and success of conservative management. A sig­nificant caveat to the interpretation of these data is that it includes all patients with postsurgical pancreatic fistula, and only a minority of patients in this study had undergone distal pancreatec­tomy [41]. Nonetheless, our approach in general has been to feed enterally wherever possible.
In comparison with pancreaticoduodenec­tomy, collections that form after distal pancre­atectomy are less likely to present with super­infection, but more likely to require prolonged drainage. Additionally, patients with postopera­tive collections after distal pancreatectomy were more likely to present in a latent fashion after discharge [42].
Ductal disruption after distal pancreatectomy can lead to a variety of complications, each of which has different specific management strat­egies. In general, we manage patients using the
32330 Preventing Pancreatic Fistula Following Distal Pancreatectomy
ISPGF criteria. Patients with grade A or B leaks are managed conservatively, with grade B pa­tients often requiring inpatient management with observation, hydration, and antibiotics.
Rarely, we have come across patients that have developed complications such as pancreatic pseudocyst following distal pancreatectomy. Our essential approach to managing these patients in­volves four steps. The first principle is resuscita­tion toward goal-directed endpoints and adequate infection control pending further management. The second is adequate anatomic information, particularly with regard to main pancreatic duct disruption and ongoing fistulous formation, with endoscopic intervention where necessary. The third is optimization of the patient to undergo prolonged conservative management, including careful attention to nutritional status, ongoing antibiotics if indicated, judicious management of electrolyte abnormalities, and overall attention to physical and psychological well-being. Fourth, when intervention is necessary, a strategy of de­liberate reintervention is preferred.
Goal-Directed Resuscitation and Infection Control
The patient presenting with latent pancreatic leak or pseudocyst frequently will present with com­plaints of abdominal pain, fever, nausea, or vom­iting. In more dramatic cases, full-blown signs of sepsis or even shock may be present. Initially, we manage these patients as we would any other postoperative intra-abdominal complication. Re­suscitation with crystalloid proceeds expeditious­ly with a goal of maintaining adequate tissue per­fusion. Hence, urine output is followed closely, with placement of a Foley catheter if there is any uncertainty as to whether adequate urine output can be recorded. Full laboratory studies, urinaly­sis, and blood cultures are obtained, and initial imaging studies including a contrast abdominal computed tomography scan are obtained. After blood cultures are drawn, antibiotic therapy is administered empirically. Individual patient-spe­cific data on history of resistant organisms and institution-specific resistance patterns are con-
sidered. Often the combination of vancomycin and a carbapenem is selected for adequate pen­etration into a potential pseudocyst cavity. Signs of severe infection, such as necrotizing features or evidence of gas-forming bacteria within the fluid collection, typically require prompt drain­age, either surgically or through radiographic means. Prompt initiation of vasopressor support and observation in a monitored bed are pursued as clinically indicated.
Further Definition of Anatomy and Source Control
The next key decision point involves defining the anatomic basis of the patient’s complication and offering targeted interventions where appropri­ate. Where CT imaging has not provided suffi­cient data, Magnetic resonance cholangiopancre­atography (MRCP) may be pursued at this point, which has the significant advantage of imaging of pancreatic ductal disruption. In most cases, we prefer obtaining an MRCP prior to consid­ering endoscopic intervention. However, where evidence of ongoing ductal leak is evident, en­doscopic retrograde cholangiopancreatography with sphincterotomy and stent placement is pur­sued in order to decompress the pancreatic ductal system. Lastly, if the clinical status warrants per­cutaneous intervention, IR-guided drain place­ment may be considered. Our primary consider­ation in this regard is the clinical status of the pa­tient and the appearance of concerning features, such as gas within the pseudocyst collection.
Optimizing Patient Clinical Status for Ongoing Conservative Management
Postoperative complications such as pancreatic fistula or pseudocyst are significant, physically and emotionally challenging complications for patients to endure. Scrupulous attention to the maintenance of the patients’ well-being as they suffer the ordeal of prolonged hospitalization or external drainage is mandatory. Careful attention to ongoing fluid losses and electrolyte abnor-
324 B. D. Nath and M. P. Callery
malities can minimize physiologic stress. Addi­tionally, it is not likely that patients can maintain adequate caloric intake in the face of the psycho­logical stress as well as the physical discomfort attendant on such a complication. Consequently, we initiate supplemental enteral nutrition quick­ly, with the recognition that supplemental feeding via a Dobhoff tube can place its own burden on the patient. Parenteral nutrition is avoided wher­ever possible. Antibiotics are typically continued for several weeks in the absence of definitive source control. Careful coordination of resourc­es is necessary if patients are to continue these treatments on an outpatient basis, whether at a rehabilitation hospital or at home. Intraperitoneal drains, whether present from the initial operation or placed under radiologic guidance, are main­tained until output has ceased or until further sur­gical intervention is pursued.
Deliberate Reintervention When Clinically Indicated
Summary
Left pancreatectomy is an attractive operation for patients with distal pancreatic disease. Nonethe­less, despite significant investigation in this area, high rates of POPF are reported across multiple centers. Few technical modalities have been con­clusively shown to prevent this complication. Re­cent studies indicating a role for mesh reinforce­ment of the staple line are encouraging, but will require further external validation. We anticipate continued growth in minimally invasive and ro­botic approaches. The adaptation of technical modalities to the minimally invasive approach may yield further improvements in preventing the complication of pancreatic stump leak. The management of the complication of pancreatic leak with or without formation of pseudocyst requires careful multidisciplinary strategies. The role of the surgeon in caring for the patient with a postoperative pancreatic leak is critical to a suc­cessful outcome and a healthy patient.
Our final approach involves reintervention when clinically indicated, preferably with minimally invasive approaches whenever necessary. The majority of patients with this complication will resolve with conservative management. How­ever, when a persistent pseudocyst has formed and is causing ongoing abdominal symptoms, surgical and occasionally endoscopic procedures such as cyst gastrostomy or cyst jejunostomy are considered (when a nonresolving mature pseudo­cyst exists). Another useful operation is internal drainage of a mature fistula tract to the jejunum, avoiding the temptation to dissect to the actual origin location of the leak. Typically operative planning requires repeat MRCP in order to define whether ongoing ductal disruption is present. Re­peat ERCP with stent exchange is considered on a case-by-case basis.
Key Points on Avoiding Complications
1. Consider gland texture, duct diameter, and gland thickness when transecting pancreatic body. Use triple-row stapler when technically feasible.
2. Consider mesh placement to reinforce staple line.
3. Octreotide administered perioperatively has never been demonstrated to provide benefit, but is utilized by a number of centers given its low cost and relative ease of administration.
4. Minimally invasive distal pancreatectomy has not been demonstrated to be superior to open pancreatectomy in terms of overall fistula rates, but is associated with decreased blood loss and shorter overall hospital stay.
5. When performed, enteric anastomoses to the distal pancreatic transection margin are asso­ciated with low rates of fistula formation, but are infrequently utilized.
32530 Preventing Pancreatic Fistula Following Distal Pancreatectomy
Key Points on Diagnosis/ Management of Complications
1. Consider pancreatic leak in the differential di­agnosis of any patient who undergoes distal pancreatectomy and experiences a significant deviation from the postoperative course.
2. No more than 50 % of pancreatic leaks are likely to be detected on the basis of intraperi­toneal drains, and axial imaging may reveal no anatomic abnormality in the setting of high drain output.
Enteral nutrition is preferred
3.
wherever pos­sible and is associated with increased rates of spontaneous fistula closure.
Endoscopic and surgical techniques
4.
may be considered for patients who develop persistent fistula or complications such as pseudocyst.
When a pseudocyst develops, consider all
5. multidisciplinary approaches, as sur
gical rein-
tervention can often be avoided.
References
1. Cogbill TH, Moore EE, Morris JA Jr, Hoyt DB, Jurkovich GJ, Mucha P Jr, et al. Distal pancreatec­tomy for trauma: a multicenter experience. J Trauma. 1991;31(12):1600–6.
2.
Callery MP, Pratt
management of pancreatic fistula. J Gastrointest Surg. 2009;13(1):163–73.
3.
Nathan H, Cameron JL, Goodwin CR, Seth
Edil BH, Wolfgang CL, et
leak after distal pancreatectomy. Ann Surg.
creatic 2009;250(2):277–81.
4.
Bassi C, Dervenis C, Butturini G, Fingerhut A,
C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138(1):8–13.
5. Pratt WB, Callery MP, Vollmer CM Jr. Risk predic­tion for development of pancreatic fistula using the ISGPF classification scheme. World J Surg. 2008;32(3):419–28.
6. Pratt WB, Callery MP, Vollmer CM Jr. The latent presentation of pancreatic fistulas. Br J Surg. 2009;96(6):641–9.
7. Facy O, Chalumeau C, Poussier M, Binquet C, Rat P, Ortega-Deballon P. Diagnosis of postoperative pan­creatic fistula. Br J Surg. 2012;99(8):1072–5.
8. Pratt W, Maithel SK, Vanounou T, Callery MP, Vollmer CM Jr. Postoperative pancreatic fistulas are not equivalent after proximal, distal, and central pan­createctomy. J Gastrointest Surg. 2006;10(9):1264–
78. Discussion 78–9.
WB, Vollmer CM Jr. Prevention and
AK,
al. Risk factors for pan-
Yeo
9. Callery MP, Pratt CM Jr. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreato­duodenectomy. J Am Coll Surg. 2013;216(1):1–14.
10. Subhedar PD, Patel SH, Kneuertz Staley CA, Sarmiento JM, et al. Risk factors for pan-
fistula after stapled gland transection. Am
creatic Surg. 2011;77(8):965–70.
Belyaev O, Munding J, Herzog T, Suelberg D, Tan-
11. napfel A, Schmidt WE, et features of the pancreatic remnant as risk factors for postoperative pancreatic fistula: a matched-pairs analysis. Pancreatology. 11(5):516–
24.
12.
Fernandez-Cruz L, Jimenez Chavarria E, Taura P,
Closa D, Boado MA, Ferrer J. Prospective random­ized trial of the effect of octreotide on pancreatic juice output after pancreaticoduodenectomy in rela­tion to histological diagnosis, duct size and leakage. HPB (Oxford). 2013;15(5):392–9.
Suc B, Msika S, Piccinini M, Fourtanier G, Hay JM,
13. Flamant Y abdominal complications following elective pancre­atic resection: a prospective, multicenter randomized controlled trial. Arch Surg. 2004;139(3):288–94. Discussion 95.
14. Abe N, Sugiyama M, Suzuki Y, Yamaguchi T, Mori T, Atomi Y. Preoperative endoscopic pancreatic stenting: a novel prophylactic measure against pan­creatic fistula after distal pancreatectomy. J Hepato­biliary Pancreat Surg. 2008;15(4):373–6.
15.
Fischer CP, Bass B, Fahy B, Aloia
pancreatic duct stenting decreases pancreatic fistula rate following left pancreatectomy. Hepatogastroen­terology. 2008;55(81):244–8.
16. Frozanpor F, Lundell L, Segersvard R, Arnelo U. The effect of prophylactic transpapillary pancreatic stent insertion on clinically significant leak rate following distal pancreatectomy: results of a prospective con­trolled clinical trial. Ann Surg. 2012;255(6):1032–6.
17. Sachs TE, Pratt WB, Kent TS, Callery MP, Vollmer CM Jr. The pancreaticojejunal anastomotic stent: friend or foe? Surgery. 2013;153(5):651–62.
18. Motoi F, Randomized clinical trial of external stent drainage of the pancreatic duct to reduce postoperative pancre­atic fistula after pancreaticojejunostomy. Br J Surg. 2012;99(4):524–31.
19. Ban D, Shimada K, Konishi M, Saiura A, M, Uesaka K. Stapler and nonstapler closure of the pancreatic remnant after distal pancreatectomy: mul­ticenter retrospective analysis of 388 patients. World J Surg. 2012;36(8):1866–73.
20. Sugimoto M, Gotohda N, Kato Y, Takahashi S, Kinoshita T, Shibasaki H, et al. Risk factor analysis and prevention of postoperative pancreatic fistula af­ter distal pancreatectomy with stapler use. J Hepato­biliary Pancreat Sci. 2013;20(5):538–44.
WB, Kent TS, Chaikof EL, Vollmer
PJ, Maithel SK,
al. Histomorphological
al. Octreotide in the prevention of intra-
, et
Egawa S, Rikiyama T, Katayose Y, Unno M.
independent
T. Transampullary
Hashimoto
326 B. D. Nath and M. P. Callery
21. Carter TI, Fong ZV, Hyslop T, Lavu H, Tan WP, Hardacre J, et trolled trial of remnant closure after distal pancre­atectomy: does the addition of a falciform patch and fibrin glue improve outcomes? J Gastrointest Surg. 2013;17(1):102–9.
22.
Sudo T, Murakami
Hashimoto Y, Nakashima A, et tomy with duct-to-mucosa pancreaticogastrostomy: novel technique for preventing postoperative pancre­atic fistula. Am J Surg. 2011;202(1):77–81.
23. Wagner M, Gloor B, Ambuhl M, Worni M, Lutz JA, Angst E, et stump decreases pancreatic fistula after distal pancre­atic resection. J Gastrointest Surg. 2007;11(3):303–8.
24.
Meniconi RL, Caronna R, Borreca D, Schiratti
Chirletti P. Pancreato-jejunostomy versus hand-sewn closure of the pancreatic stump to prevent pancreatic fistula after distal pancreatectomy: a retrospective analysis. BMC Surg. 2013;13:23.
25.
Kleeff J, Diener MK, Z’Graggen
M, Bachmann J, et
for surgical failure in 302 consecutive cases.
factors Ann Surg. 2007;245(4):573–82.
26.
Sepesi B, Moalem J, Galka E, Salzman P
LO. The influence of staple size on fistula formation following distal pancreatectomy. J Gastrointest Surg. 2012;16(2):267–74.
27.
Diener MK, Seiler CM, Rossion I, Kleeff J, Glane
mann M, Butturini G, et hand-sewn closure after distal pancreatectomy (DIS­PACT): a randomised, controlled multicentre trial. Lancet. 2011;377(9776):1514–22.
28.
Bilimoria MM, Cormier JN, Mun
DB, Pisters PW. Pancreatic leak after left pancreatec­tomy is reduced following main pancreatic duct liga­tion. Br J Surg. 2003;90(2):190–6.
29.
Thaker RI, Matthews BD, Linehan DC, Strasber
SM, Eagon JC, Hawkins WG. Absorbable mesh re­inforcement of a stapled pancreatic transection line reduces the leak rate with distal pancreatectomy. J Gastrointest Surg. 2007;11(1):59–65.
30.
Hamilton NA, Porembka MR, Johnston
Strasberg SM, Linehan DC, et ment of pancreatic transection decreases incidence of pancreatic occlusion failure for left pancreatectomy: a single-blinded, randomized controlled trial. Ann Surg. 2012;255(6):1037–42.
31.
Idrees K, Edler JR, Linehan DC, Strasberg SM,
Jacques D, Hamilton of mesh my. HPB (Oxford). 2013;15(11):898–993.
reinforcement of stapled left pancreatecto-
dual-institution randomized con-
al. A
Y, Uemura K, Hayashidani Y,
al. Roux-en-Y drainage
al. Distal pancreatectomy: risk
NA, et
al. Distal pancreatec-
K, Hinz U, Wagner
al. Efficacy
al. Mesh reinforce
al. Cost benefit analysis
of the pancreatic
M,
, Schoeniger
of stapler versus
Y, Lee JE, Evans
FM, Gao F,
32.
Magge D, Gooding W, Choudry H, Steve
J, Zureikat A, et minimally invasive and open distal pancreatec­tomy for ductal adenocarcinoma. JAMA Surg. 2013;148(6):525–31.
33. Tran Cao HS, Lopez N, Chang DC, Lowy AM, Bou­vet M, Baumgartner JM, et tive outcomes with minimally invasive
a
-
g
-
atectomy: results from a population-based analysis. JAMA Surg. 149(3):237–43.
34.
Kooby DA, Gillespie T, Bentrem
Schmidt MC, Merchant NB, et atectomy: a multicenter and open approaches. Ann Surg. 2008;248(3):438–
46.
35.
Zureikat AH, Moser AJ, Boone
nati M, Zeh HJ 3rd. 250 robotic pancreatic resections: safety and feasibility. Ann Surg. 2013;258(4):554–9. Discussion 9–62.
36.
Daouadi M, Zureikat AH, Zenati
Tsung A, Bartlett DL, et invasive distal pancreatectomy is superior to the lap aroscopic technique. Ann Surg. 2013;257(1):128–32.
37. Conlon KC, Labow D, Leung D, Smith A, Jarnagin W, Coit DG, et al. Prospective randomized clinical trial of the value of intraperitoneal drainage after pancreatic resection. Ann Surg. 2001;234(4):487–93. Discussion 93–4.
38.
Pannegeon V, Pessaux P
MP, Kianmanesh R, Belghiti J. Pancreatic fistula after distal pancreatectomy: predictive risk factors and value of conservative treatment. Arch Surg. 2006;141(11):1071–6. Discussion 6.
39.
Paulus EM, Zarzaur
peritoneal drainage of the surgical bed after elective distal pancreatectomy: is it necessary? Am J Surg. 2012;204(4):422–7.
40. Melloul E, Raptis DA, Clavien P level of agreement on the management of postopera­tive pancreatic fistula: results of an international sur­vey. HPB (Oxford). 2013;15(4):307–14.
41.
Klek S, Sierzega M, Turczynowski L, Szybinski P,
Szczepanek K, Kulig J. Enteral and parenteral nutri­tion in the conservative treatment of pancreatic fis­tula: a randomized clinical trial. Gastroenterology. 2011;141(1):157–63, 63 e1.
42.
, Sima CS, Getrajdman GI, Brown KT, Covey
Vin Y
A, Brennan MF, et postpancreatectomy of 908 patients resected at a single institution between 2000 and 2005. J Am Coll Surg. 2008;207(4):490–8.
al. Comparative ef
al. Improved periopera-
comparison of laparoscopic
al. Robot-assisted minimally
, Sauvanet A, Vullierme
BL, Behrman SW. Routine
al. Management and outcomes of
fistula, leak, and abscess: results
fectiveness of
distal pancre-
D, Nakeeb A,
al. Left-sided pancre-
BA, Bartlett DL, Ze-
MS, Choudry H,
A, Lesurtel M. Poor
J, Steel
-